NCT06958328 2026-04-08
LAP100
NRG Oncology
Phase 3 Recruiting
Clinical Trials
10 trialsNCT06998940 2026-03-27
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
SWOG Cancer Research Network
Phase 3 Recruiting
NCT06953999 2026-03-04
A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer
Akeso
Phase 3 Recruiting
NCT07383922 2026-02-04
A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer
FutureGen Biopharmaceutical (Beijing) Co., Ltd
Phase 3 Not yet recruiting
NCT04329949 2023-11-18
RELIANT
Corcept Therapeutics
Phase 3 Terminated
NCT02993731 2023-11-15
CanStem111P
Sumitomo Pharma America, Inc.
Phase 3 Completed
NCT01964430 2023-06-28
apact
Celgene
Phase 3 Completed
NCT01836432 2020-05-28
PILLAR
Lumos Pharma
Phase 3 Terminated
NCT00844649 2019-11-25
Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas
Celgene
Phase 3 Completed
NCT02506842 2016-08-11
Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine Versus Oxaliplatin Plus Folinic Acid and Fluorouracil for Gemcitabine-Refractory Pancreatic Cancer After Curative Resection
Fudan University
Phase 3 Unknown